MVA-BN filovirus vaccine - Bavarian Nordic
Alternative Names: Ebola Marburg virus vaccine - Bavarian Nordic; Marburg Ebola virus vaccine - Bavarian Nordic; Modified Vaccinia Ankara Bavarian Nordic Marburg Ebola vaccine; MVA-BN Filo; MVA-BN-EBOV-MARV; MVA-BN-MARV-EBOV; MVA-BN®Filo vaccine; MVABEALatest Information Update: 29 Dec 2023
At a glance
- Originator Bavarian Nordic
- Developer Bavarian Nordic; Crucell; Janssen Vaccines and Prevention B.V; London School of Hygiene & Tropical Medicine; University of Maryland, Baltimore; Wellcome Trust
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Ebola virus infections
- Phase II Marburg virus disease
Most Recent Events
- 13 Dec 2023 Janssen terminates a phase III trial for Ebola virus infections (In adolescents, In children, In the elderly, Prevention, In adults, In infants, In neonates) in USA, Burkina Faso, France, Kenya, Tanzania, Uganda, and the UK due to the pandemic with only one participant in follow up, as the impact on the safety was determined to be negligible (NCT02661464)
- 22 Sep 2022 Janssen completes a phase II trial in Ebola virus infections (Prevention, In infants) in Guinea and Sierra Leone (NCT03929757)
- 19 Sep 2022 London School of Hygiene and Tropical Medicine in collaboration with University of Sierra Leone, Janssen Vaccines & Prevention initiates enrolment in a phase II clinical trial for Ebola virus infections (Prevention, In children, In adolescents, In adults) in Sierra Leone (IM) (NCT05284097)